Key genetic mutations frequently observed in CRC, such as those in APC, KRAS, TP53, MYC, and SMAD4, have been shown to drive global metabolic alterations by modulating the expression and activity of critical metabolic enzymes (10–12). Here, TP53 is linked to colorectal carcinoma.